PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.11%
Revenue growth above 1.5x CSIQ's 3.70%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
294.55%
Positive gross profit growth while CSIQ is negative. John Neff would see a clear operational edge over the competitor.
-215.39%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-262.81%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-150.75%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-149.67%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-149.67%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.62%
Share count expansion well above CSIQ's 0.16%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.62%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
120.36%
OCF growth of 120.36% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
103.24%
FCF growth of 103.24% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
657.47%
5Y revenue/share CAGR at 50-75% of CSIQ's 1264.06%. Martin Whitman would worry about a lagging mid-term growth trajectory.
53.03%
3Y revenue/share CAGR at 75-90% of CSIQ's 59.67%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
127.48%
OCF/share CAGR of 127.48% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-88.02%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
-2819.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1330.25%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
72.75%
Below 50% of CSIQ's 827.04%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-3.62%
Negative 3Y equity/share growth while CSIQ is at 9.47%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.64%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
3.06%
We show growth while CSIQ is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-5.28%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.84%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
18.12%
We have some new debt while CSIQ reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-16.98%
Our R&D shrinks while CSIQ invests at 61.12%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.99%
We cut SG&A while CSIQ invests at 2.83%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.